NO20085290L - Metode - Google Patents

Metode

Info

Publication number
NO20085290L
NO20085290L NO20085290A NO20085290A NO20085290L NO 20085290 L NO20085290 L NO 20085290L NO 20085290 A NO20085290 A NO 20085290A NO 20085290 A NO20085290 A NO 20085290A NO 20085290 L NO20085290 L NO 20085290L
Authority
NO
Norway
Prior art keywords
mage
relates
probes
methods
specific
Prior art date
Application number
NO20085290A
Other languages
English (en)
Norwegian (no)
Inventor
Thierry Coche
Gabriele Annemarie Beer
Olivier Gruselle
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20085290L publication Critical patent/NO20085290L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20085290A 2006-06-21 2008-12-18 Metode NO20085290L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
NO20085290L true NO20085290L (no) 2009-01-19

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085290A NO20085290L (no) 2006-06-21 2008-12-18 Metode

Country Status (27)

Country Link
US (1) US8936919B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041308B1 (cg-RX-API-DMAC7.html)
JP (2) JP2009540812A (cg-RX-API-DMAC7.html)
KR (1) KR101455589B1 (cg-RX-API-DMAC7.html)
CN (1) CN101506383B (cg-RX-API-DMAC7.html)
AU (1) AU2007263019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656909A1 (cg-RX-API-DMAC7.html)
CO (1) CO6140072A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2041308T3 (cg-RX-API-DMAC7.html)
EA (1) EA016347B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389513T3 (cg-RX-API-DMAC7.html)
GB (1) GB0612342D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120761T1 (cg-RX-API-DMAC7.html)
IL (1) IL195975A (cg-RX-API-DMAC7.html)
MA (1) MA30565B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008016493A (cg-RX-API-DMAC7.html)
MY (1) MY147511A (cg-RX-API-DMAC7.html)
NO (1) NO20085290L (cg-RX-API-DMAC7.html)
NZ (1) NZ573809A (cg-RX-API-DMAC7.html)
PL (1) PL2041308T3 (cg-RX-API-DMAC7.html)
PT (1) PT2041308E (cg-RX-API-DMAC7.html)
SI (1) SI2041308T1 (cg-RX-API-DMAC7.html)
UA (1) UA95956C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007147876A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810695B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE209690T1 (de) * 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ATE522620T1 (de) * 2002-11-14 2011-09-15 Wayne John Cancer Inst Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
IL195975A (en) 2012-08-30
PL2041308T3 (pl) 2012-11-30
US8936919B2 (en) 2015-01-20
GB0612342D0 (en) 2006-08-02
ES2389513T3 (es) 2012-10-26
HRP20120761T1 (hr) 2012-10-31
CA2656909A1 (en) 2007-12-27
CY1113290T1 (el) 2016-04-13
HK1127627A1 (en) 2009-10-02
WO2007147876A2 (en) 2007-12-27
JP2009540812A (ja) 2009-11-26
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2013046630A (ja) 2013-03-07
SI2041308T1 (sl) 2012-10-30
EP2041308B1 (en) 2012-07-11
DK2041308T3 (da) 2012-10-08
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
US20120040341A1 (en) 2012-02-16
NZ573809A (en) 2011-12-22
JP5705191B2 (ja) 2015-04-22
BRPI0713599A2 (pt) 2012-11-06
AU2007263019B2 (en) 2012-11-08
UA95956C2 (uk) 2011-09-26
WO2007147876A3 (en) 2008-05-15
CO6140072A2 (es) 2010-03-19
CN101506383A (zh) 2009-08-12
CN101506383B (zh) 2013-08-28
KR101455589B1 (ko) 2014-10-28
AU2007263019A1 (en) 2007-12-27
KR20090034900A (ko) 2009-04-08
IL195975A0 (en) 2009-09-01
EA016347B1 (ru) 2012-04-30
MY147511A (en) 2012-12-31
EP2041308A2 (en) 2009-04-01
PT2041308E (pt) 2012-10-09

Similar Documents

Publication Publication Date Title
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
NO20084546L (no) Diagnostikk og behandlinger for tumorer
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
TW200740844A (en) Novel MAdCAM antibodies
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
EP2668296A2 (en) Colon cancer gene expression signatures and methods of use
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2007141280A3 (en) Proteins
WO2009143181A3 (en) Micro-rna profile in human saliva and its use for detection of oral cancer
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application